TABLE 5.
Base-case results.
| C | E | CER | ICER | Special | |
|---|---|---|---|---|---|
| API | 5,877.399 | 0.940 | 6,252.553 | −187017.543 | - |
| RIV | 3,072.136 | 0.955 | 3,216.897 | - | dominant |
| DAB | 3,926.160 | 0.952 | 4,124.119 | −284674.922 | - |
| VKA | 4,325.386 | 0.820 | 5,274.862 | −9,283.339 | - |
QALY, quality-adjusted life year; ICER, incremental cost-effectiveness ratio; CER, the cost-effectiveness ratio; API, apixaban; RIV, rivaroxaban; DAB, dabigatran; LMWH/VKA, low molecular weight heparin followed by vitamin K antagonist.